Insider Buying: Tango Therapeutics, Inc. (NASDAQ:TNGX) Director Acquires $36,200.00 in Stock

Tango Therapeutics, Inc. (NASDAQ:TNGX) Director Mace Rothenberg purchased 10,000 shares of the stock in a transaction that occurred on Thursday, November 14th. The shares were acquired at an average cost of $3.62 per share, with a total value of $36,200.00. Following the completion of the transaction, the director now owns 21,250 shares in the company, valued at $76,925. This trade represents a 88.89 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Mace Rothenberg also recently made the following trade(s):

• On Monday, November 18th, Mace Rothenberg purchased 10,000 shares of Tango Therapeutics stock. The shares were bought at an average price of $3.78 per share, with a total value of $37,800.00.

Tango Therapeutics Trading Up 6.0 %

Shares of NASDAQ TNGX opened at $4.08 on Thursday. Tango Therapeutics, Inc. has a 12-month low of $2.70 and a 12-month high of $13.01. The firm has a market capitalization of $438.27 million, a price-to-earnings ratio of -3.26 and a beta of 0.88. The firm has a 50 day moving average of $6.43 and a 200 day moving average of $8.09.

Institutional Trading of Tango Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of TNGX. Mirae Asset Global Investments Co. Ltd. increased its holdings in Tango Therapeutics by 32.6% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 28,964 shares of the company’s stock worth $230,000 after acquiring an additional 7,128 shares in the last quarter. SG Americas Securities LLC boosted its stake in shares of Tango Therapeutics by 16.0% in the first quarter. SG Americas Securities LLC now owns 30,429 shares of the company’s stock worth $242,000 after acquiring an additional 4,203 shares during the period. Vanguard Group Inc. boosted its stake in shares of Tango Therapeutics by 3.4% in the first quarter. Vanguard Group Inc. now owns 3,080,885 shares of the company’s stock worth $24,462,000 after acquiring an additional 101,673 shares during the period. Price T Rowe Associates Inc. MD grew its position in shares of Tango Therapeutics by 12.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 12,771 shares of the company’s stock worth $102,000 after purchasing an additional 1,426 shares in the last quarter. Finally, Paloma Partners Management Co bought a new stake in Tango Therapeutics during the 1st quarter valued at approximately $80,000. Hedge funds and other institutional investors own 78.99% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. B. Riley cut their price objective on shares of Tango Therapeutics from $16.00 to $8.00 and set a “buy” rating on the stock in a research report on Monday, November 11th. Wedbush lifted their target price on Tango Therapeutics from $11.00 to $13.00 and gave the stock an “outperform” rating in a report on Thursday, August 8th. HC Wainwright reaffirmed a “buy” rating and set a $13.00 price objective on shares of Tango Therapeutics in a research report on Friday, November 8th. Finally, Guggenheim decreased their target price on Tango Therapeutics from $18.00 to $8.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Tango Therapeutics currently has an average rating of “Buy” and an average target price of $13.14.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.